CCG
AMPH icon

Chatham Capital Group’s Amphastar Pharmaceuticals AMPH Stock Holding History

Chatham Capital Group’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,295
Closed -$1.01M – 196
2024
Q4 		$1.01M Sell
27,295
-395
-1% -$18.1K 0.17% 126
2024
Q3 		$1.34M Buy
+27,690
New +$1.22M 0.22% 108

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Chatham Capital Group's AMPH Position: Q1 2025 in Review

Chatham Capital Group sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2025, closing a stake of 27,295 shares — an estimated $1.01M sold.

Chatham Capital Group first reported a position in AMPH in Q3 2024 and held it in 2 quarters. The position peaked at $1.34M in Q3 2024. 241 funds tracked by Wall St. Rank hold AMPH as of Q1 2025.

  • Chatham Capital Group reported no remaining Amphastar Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Chatham Capital Group sold 27,295 Amphastar Pharmaceuticals shares in Q1 2025, an estimated $1.01M.
  • Chatham Capital Group first reported a position in Amphastar Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Chatham Capital Group's Amphastar Pharmaceuticals position peaked at $1.34M in Q3 2024.
  • 241 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2025.

Based on Chatham Capital Group's 13F filing for Q1 2025, filed 10 Apr 2025.